Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other, Topics

Naming Novo Names: Who Could Be the Next CEO? 

Here is a brief preview of this blast: With Novo Nordisk preparing for the succession of Lars Fruergaard Jørgensen as CEO (previous FENIX insight), the key question now is: who will take on the role? In Novo’s investor call to discuss its leadership transition plans, the company emphasized that its strategy has not changed and that it will continue to execute its current plans. As such, this seems to suggest that its next CEO may be more likely to fall in line with its previous patterns (e.g., internal hire) rather than someone who is viewed as more transformative. Below, FENIX presents a selection of both internal and external candidates as well as an assessment of the likelihood that they are on the CEO search committee’s short list.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.